Snyder, Gretchen L.
Prickaerts, Jos
Wadenberg, Marie-Louise
Zhang, Lei
Zheng, Hailin
Yao, Wei
Akkerman, Sven
Zhu, Hongwen
Hendrick, Joseph P.
Vanover, Kimberly E.
Davis, Robert
Li, Peng
Mates, Sharon
Wennogle, Lawrence P.
Funding for this research was provided by:
National Institute of Mental Health (R43 MH067488-01)
Article History
Received: 17 November 2015
Accepted: 7 June 2016
First Online: 24 June 2016
Compliance with ethical standards
:
: This work was supported, in part, by Intra-Cellular Therapies, Inc. (ITI). ITI-214 is an investigational new drug under development by ITI. Drs. Snyder, Zhu, Yao, Li, Zhang, Zheng, Hendrick, Vanover, Wennogle, and Mates were full-time employees of ITI while the experiments were conducted. Dr. Davis was a paid consultant of ITI during the course of these studies and is currently a full-time employee of ITI. Drs. Akkerman and Prickaerts are investigators at Maastricht University, The Netherlands. Dr. Wadenberg was an Associate Professor/Lecturer at Linnaeus University, Kalmar, Sweden during the conduct of these studies.
: This work was supported, in part, by funding from the NIH (R43 MH067488-01 to Intra-Cellular Therapies Inc.).